Autopsy report · NCT02744820

Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics

“It was considered by the sponsor that the study objective has been met by dosing 13 instead of 15 patients”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 5 months before it stopped.
• 34 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Genmedica Therapeutics S.L.

Sponsor type

Industry

Conditions

Healthy; Type 2 Diabetes Mellitus

Interventions

GMC-252-L-Lysine Salt; Placebo

Participants

34

Sites

2

Countries

United Kingdom

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.